About Palisade Bio, Inc. Common Stock
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Market Cap
$0.00B
Employees
9
Listed Since
April 28, 2021
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.palisadebio.comPhone
(858) 704-4900
Headquarters
7750 EL CAMINO REAL, SUITE 5200
CARLSBAD, CA 92009
CIK
0001357459